Published on April 29, 2026
mbiomics GmbH, a Munich-based techbio venture, was operating within the burgeoning field of microbiome therapeutics, focusing on innovative solutions for cancer treatment. The company has made notable strides in developing a live bacterial product aimed at enhancing immune checkpoint inhibitors, which currently represent a significant component of cancer therapies.
- Demis Hassabis Reflects on AI Evolution and Future Aspirations
- X-Energy Secures $1.02 Billion in Landmark IPO
- Proxima Revolutionizes Fitness with AI-Driven Workouts
- Pixel 11 Set to Reintroduce Notification LED with 'Pixel Glow'
- China Sheds New Light on Meta’s Ambitious Manus AI Acquisition
- Victory Giant's $2.6B Debut Propels Ambitious AI Vision